Safety and efficacy of Suzetrigine (VX-548) for acute moderate to severe pain in adults; a systematic review and meta-analysis
Authors' conclusion
Suzetrigine was better tolerated and more efficacious than placebo
Study context
- Population
- Adults with moderate to severe acute pain
- Participants
- 2,855 adults · 5 Randomized Controlled Trials (RCTs)
- Comparison
- Suzetrigine vs placebo or HB/APAP
- Outcome
- Adverse events
Pooled result
As reported in the abstract
Relative risk (95% CI)
Suzetrigine vs Placebo
0.86(0.77–0.96)
Suzetrigine vs HB/APAP
0.81(0.74–0.89)
Further pooled results
| Outcome | SMD (95% CI) | |
|---|---|---|
| SPID48 (post-operative) · 48 hSuzetrigine vs Placebo · I2 = 9% | 0.42 (0.31–0.53) | |
| −0.500.51Difference (linear scale) |
SPID48 (post-operative) · 48 h
- SPID48: no superiority vs HB/APAP
Safety
Individual adverse events
- Nausea and dizziness most common AEs with Suzetrigine vs placebo
Original publication
Safety and efficacy of Suzetrigine (VX-548) for acute moderate to severe pain in adults; a systematic review and meta-analysis. J Clin Anesth. Published 4 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →